Disc Medicine (IRON) stock is in focus after the company reported updated clinical data at the EHA Annual Meeting in Stockholm, highlighting results from its RALLY MF and HELIOS trials in hematologic disorders.

At a share price of $69.83, Disc Medicine has seen a 90 day share price return of 18.02%, while the year to date share price return is down 11.71% and the 1 year total shareholder return is 39.41%.

If fresh trial data has your attention, this is a good moment to see which other healthcare companies linked to artificial intelligence are on the move with the Simply Wall St screener for 40 healthcare AI stocks

With Disc Medicine stock trading at $69.83 and an indicated intrinsic discount of about 64%, plus a sizeable gap to the current analyst price target, you have to ask: is there genuine value here, or is the market already pricing in future growth?

Preferred Price-to-Book Multiple of 3.9x: Is It Justified?

Disc Medicine is currently trading on a price-to-book, or P/B, ratio of 3.9x, compared with an estimated fair value that suggests the stock is trading at a sizeable discount and an analyst price target that is higher than the last close of $69.83.

The P/B ratio compares the market value of the company to its book value, which is essentially its net assets on the balance sheet. For early stage biopharmaceutical companies like Disc Medicine that are still loss making and focused on developing a pipeline, investors often lean on P/B because traditional earnings based metrics such as P/E are not yet meaningful.

In this case, the SWS DCF model points to a future cash flow value of about $195.50 per share, while the market is pricing Disc Medicine stock at $69.83. That gap suggests investors are applying a higher P/B multiple than the US Biotechs industry average of 2.4x and the peer average of 3.6x, even though the company currently reports no revenue and a loss of $241.60m, and is forecast to remain unprofitable over the next 3 years.

Compared with those benchmarks, Disc Medicine's 3.9x P/B looks relatively expensive versus both its broader industry and its closer peer set. This implies the market is already assigning a premium to the balance sheet and pipeline potential versus comparable biotechs.

Result: Price-to-book of 3.9x (OVERVALUED)

However, Disc Medicine's lack of revenue and a reported loss of $241.60m, alongside forecasts that it may remain unprofitable for 3 years, could challenge that premium.

Another View on Disc Medicine Stock: Discounted Cash Flow

While the P/B ratio suggests Disc Medicine stock is priced at a premium to peers, the SWS DCF model points in the opposite direction, indicating a future cash flow value of about $195.50 per share versus the current $69.83, or roughly a 64% discount.

That kind of gap raises a practical question for investors: is the market overpaying for assets on the balance sheet, or underestimating the potential cash flows from Disc Medicine's hematology pipeline?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Disc Medicine for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Disc Medicine reflecting both optimism around its pipeline and questions around valuation, this is a moment to look closely at the full picture yourself. To weigh those concerns and potential upsides side by side, review the 2 key rewards and 2 important warning signs

Looking For More Investment Ideas Beyond Disc Medicine?

If Disc Medicine has sharpened your focus on valuation and risk, do not stop here. Use focused stock lists to uncover other opportunities that fit your approach.

• Target potential upside in quality companies trading below their estimated worth by reviewing the 44 high quality undervalued stocks.
• Strengthen income potential with companies offering higher yields and resilient payouts through the 9 dividend fortresses.
• Prioritize capital preservation by zeroing in on companies flagged with lower risk scores in the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.